---
id: vaccine-platforms-and-antimicrobials
name: Vaccine Platforms & Antimicrobials
family: technological
tier: active
url: https://futuremap.talin.digital/e/vaccine-platforms-and-antimicrobials/
license: CC-BY-NC-4.0
---

# Vaccine Platforms & Antimicrobials

## Maturity
3/5 — Vaccine platforms are demonstrably mature; the antimicrobial half is a market failure with a thin pipeline. The score is the blend and the halves must be written separately.

Capability 4 · deployment 3 · absorption 3 · bound by incentives · deteriorating

Source: WHO, Antibacterial agents in clinical and preclinical development, 14 Jun 2024 (cutoff 31 Dec 2023): 97 products in clinical development, only 3 in pre-registration. Post-approval insolvencies: Achaogen Ch.11 Apr 2019 (Zemdri approved Jun 2018, ~$800k revenue by end-2018, assets sold $16m against ~$300m development cost), Aradigm Feb 2019, Melinta Dec 2019 (2023–2024)

## What it is
Rapid-response vaccine technologies and the development of new classes of antibiotic and antimicrobial agent.

## What it does
It is the enabler standing between a pathogen and a pandemic, and between antimicrobial resistance and a return to pre-antibiotic medicine. Its two halves are moving in opposite directions.

## Common misconception
That vaccine platform success implies antimicrobial success. Vaccines had a demonstrated pandemic response; the antibiotic pipeline is nearly empty, and for market reasons rather than scientific ones.

## Steepens
- Zoonotic and Antimicrobial Resistance Risk (zoonotic-and-antimicrobial-resistance-risk) — large
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — moderate
- Food System Transformation (food-system-transformation) — moderate

## What would change its gradient
- Pull incentives — subscription or market-entry rewards that decouple revenue from volume
- Stewardship, which reduces resistance pressure and cuts revenue further
- Surveillance capacity, which determines how early anything is seen
